Loading
Life sciences · Journal article
Expert Review of Anti-infective Therapy · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Fluoroquinolones have been in clinical use for more than 40 years and have benefitted hundreds of millions of patients in both hospital and community settings.Areas Covered Black box or prominent safety warnings from regulating agencies about rare but serious adverse events has mandated a rethinking about when and where to use these antimicrobial agents. Additionally, the critical role of some fluoroquinolones for treatment of Mycobacteria tuberculosis (TB) infection raises concerns about their use for mild community acquired infections. Regardless, fluoroquinolones remain entrenched in a broad range of infectious diseases treatment guidelines, including tuberculosis, and are integral agents in antimicrobial stewardship programs.Expert opinion Fluoroquinolones are essential agents for treating infectious diseases and appropriate use of these important drugs, along with all of the antimicrobial drug classes remains of paramount importance.